Hangzhou Biomedicine and High-Performance Medical Devices Project’
- Importance: Since 2015, China has issued a number of innovative medical device documents to support innovative medical devices at the regulatory and approval process levels. The "14th Five-Year Plan" National Health Plan clearly states that medical devices that meet the requirements and are urgently needed for clinical use will be accelerated for review and approval. In July 2023, the National Development and Reform Commission issued the "Announcement on Public Comments on the Guidance Catalog for Industrial Structural Adjustment (2023 Edition, Draft for Comments)", and high-end medical devices were included in the encouraged category. National Medical Products Administration issued the "Special Review Procedure for Innovative Medical Devices" and the "Priority Approval Procedure for Medical Devices", aiming to accelerate the launch of innovative products and urgently needed clinical products. In this background, Many provinces have released key special project plans for "Innovative medical devices" during the 14th Five-Year Plan period.
- Concrete project plan: Hangzhou is expected to construct of 18 biomedicine and high-performance medical equipment projects. The project includes the construction of life science industrial park, production base, and R&D center. The total projects plan to invest 26.1 billion RMB during the 14th Five-Year Plan period.
- Business opportunity: Companies involved in the manufacturing of laboratory equipment, scientific instruments, and bioprocessing technologies can benefit from the establishment of new life science industrial parks. They can supply cutting-edge equipment and technologies to support research, development, and production activities. Besides, life science industrial parks often require advanced IT infrastructure, data management systems, and digital solutions. Companies offering IT services, software development, data analytics, and cybersecurity can support the digital transformation and connectivity needs of these facilities.
Call to action
The Swedish Life Science Platform in China is run by Team Sweden (The Embassy of Sweden, The Swedish Consulate General in Shanghai, The Swedish Consulate in Hong Kong and Business Sweden). We have jointly chosen to prioritize life science as a platform to promote Swedish innovation and presence in the Chinese market.
After the disruption caused by the Covid-19 pandemic, the Swedish Life Science Platform is resuming its activities in 2024. Please contact judy.zhao@business-sweden.se for more details.